F. Anthony Greco - Concepedia

Author

F. Anthony Greco

Also Known As

F A Greco, F ANTHONY GRECO, F Anthony Greco, F GRECO, F Greco, F Gréco, F MURATORI, F. A. Greco, F. ANTHONY GRECO, F. Anthony Greco

635

Publications

21.8K

Citations

H-Index

204

Concepts

All Affiliations

Sarah Cannon Tennessee Oncology Vanderbilt University Vanderbilt University Medical Center Università Campus Bio-Medico

About

F. Anthony Greco is an author at Sarah Cannon specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	53	162	10.3K
2	Health Sciences	27	51	2.8K
3	Arts	2	2	26
4	Engineering	2	2	82
5	Public Health	1	1	26

F. Anthony Greco

272

Publications

18.6K

Citations

H-Index

Page 1

	Year	Citations
Treatment of Disseminated Germ-Cell Tumors with Cisplatin, Bleomycin, and either Vinblastine or Etoposide Stephen D. Williams, Robert Birch, Lawrence H. Einhorn, New England Journal of Medicine Cancer ResearchDisseminated Germ-cell TumorsSurgical OncologyMalignant DiseaseMedicine	1987	1.2K
Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Karim Fizazi, F. Anthony Greco, Nicholas Pavlidis, Annals of Oncology Esophageal CancerMedicineCancer ManagementPathologyCancer Registration	2015	442
Rituximab as First-Line and Maintenance Therapy for Patients With Indolent Non-Hodgkin’s Lymphoma John D. Hainsworth, Sharlene Litchy, Howard A. Burris, Journal of Clinical Oncology	2002	417
Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. Lawrence H. Einhorn, Stephen D. Williams, Patrick J. Loehrer, Journal of Clinical Oncology Tumor BiologyUrologyOncologyOptimal DurationModerate Extent	1989	374
Molecular Gene Expression Profiling to Predict the Tissue of Origin and Direct Site-Specific Therapy in Patients With Carcinoma of Unknown Primary Site: A Prospective Trial of the Sarah Cannon Research Institute John D. Hainsworth, Mark S. Rubin, David R. Spigel, Journal of Clinical Oncology	2012	367
Single-Agent Rituximab as First-Line and Maintenance Treatment for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Phase II Trial of the Minnie Pearl Cancer Research Network John D. Hainsworth, Sharlene Litchy, John H. Barton, Journal of Clinical Oncology	2003	350
Maximizing Therapeutic Benefit of Rituximab: Maintenance Therapy Versus Re-Treatment at Progression in Patients With Indolent Non-Hodgkin's Lymphoma—A Randomized Phase II Trial of the Minnie Pearl Cancer Research Network John D. Hainsworth, Sharlene Litchy, Don W. Shaffer, Journal of Clinical Oncology	2005	331
Tracheoesophageal Fistula Formation in Patients With Lung Cancer Treated With Chemoradiation and Bevacizumab David R. Spigel, John D. Hainsworth, Denise A. Yardley, Journal of Clinical Oncology Esophageal CancerCancer ManagementSurgeryLung Cancer TreatedFistula Development	2009	296
Phase III Trial of Vandetanib Compared With Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer Ronald B. Natale, Sumitra Thongprasert, F. Anthony Greco, Journal of Clinical Oncology	2011	296
Prognostic factors for favorable outcome in disseminated germ cell tumors. Robert Birch, Stephen D. Williams, A. J. Cone, Journal of Clinical Oncology Prognostic FactorsSurgical OncologyIndiana UniversityCancer ManagementEpidemiology Of Cancer	1986	295

Page 1